Intra-Cellular Therapies (ITCI) Psychotic Reaction In After-Hours; Green Light in Japan for Aegerion Pharma’s (AEGR) MTP Inhibitor


Shares of Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) slumped more than 65% to touch a new 52-week low in after-hours trading Wednesday as the biopharmaceutical company said that its ITI-007 did not separate from placebo – on the primary endpoint – in the second late-stage clinical trial evaluating its investigational drug in schizophrenia patients

ITCI stock finished the regular session in positive territory by 2.00% (or +$0.83) at $42.35 with a total volume of 2.15M shares traded, representing a large increase in activity versus its average volume (3m) of 413,277

Intra-Cellular Therapies, which discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS), has 29.40M Shares Outstanding. At close on Wednesday, the company had a Market Capitalization of $1.83B and ITCI stock one-year range was between $22.41 and $59.96 per share



Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) shares soared over 30% in the extended session Wednesday after the company said that Japan’s Ministry of Health, Labor & Welfare gave green light to its microsomal triglyceride transfer protein (MTP) inhibitor Juxtapid ( lomitapide) capsules for patients with homozygous familial hypercholesterolemia, a rare genetic disease.

AEGR stock closed at $2.49, down $0.26 (or -9.45%) and 767.75k of its shares changed hands during the day

Aegerion Pharmaceuticals, which develops and commercializes therapies for patients with debilitating rare diseases, has 29.51M Shares Outstanding, Market Capitalization (intraday) of $73.49M and AEGR stock 52-week range is from $1.23 to $16.63 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at